MED-C took on renewed importance when MOLDX issued a revised lung cancer gene panel LCD in September 2016. In return for greater coverage, labs are to follow new, expanded and detailed requirements for patient genomic and clinical outcome data which is to be contributed to a public non profit registry that must meet an extensive list of requirements (here).
To help you keep up with MED-C, here are some key links.
- MED-C organization website, here.
- Press release on the recently expanded MED-C expert panel, here.
- Press release on MED-C's IRB approval, here.
- ClinicalTrials.gov page for the MED-C registry (NCT02900248), here.